JP2023509186A5 - - Google Patents

Info

Publication number
JP2023509186A5
JP2023509186A5 JP2022541984A JP2022541984A JP2023509186A5 JP 2023509186 A5 JP2023509186 A5 JP 2023509186A5 JP 2022541984 A JP2022541984 A JP 2022541984A JP 2022541984 A JP2022541984 A JP 2022541984A JP 2023509186 A5 JP2023509186 A5 JP 2023509186A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
alkoxy
alkyl
formula
product according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022541984A
Other languages
English (en)
Japanese (ja)
Other versions
JP7763761B2 (ja
JP2023509186A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/000006 external-priority patent/WO2021140418A1/en
Publication of JP2023509186A publication Critical patent/JP2023509186A/ja
Publication of JP2023509186A5 publication Critical patent/JP2023509186A5/ja
Application granted granted Critical
Publication of JP7763761B2 publication Critical patent/JP7763761B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022541984A 2020-01-08 2021-01-07 Betブロモドメイン阻害剤およびジペプチジルペプチダーゼ4阻害剤の組合せによる主要有害心血管イベント(mace)の治療方法および/または予防方法 Active JP7763761B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062958474P 2020-01-08 2020-01-08
US62/958,474 2020-01-08
PCT/IB2021/000006 WO2021140418A1 (en) 2020-01-08 2021-01-07 Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor

Publications (3)

Publication Number Publication Date
JP2023509186A JP2023509186A (ja) 2023-03-07
JP2023509186A5 true JP2023509186A5 (cg-RX-API-DMAC10.html) 2024-01-16
JP7763761B2 JP7763761B2 (ja) 2025-11-04

Family

ID=76788523

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022541984A Active JP7763761B2 (ja) 2020-01-08 2021-01-07 Betブロモドメイン阻害剤およびジペプチジルペプチダーゼ4阻害剤の組合せによる主要有害心血管イベント(mace)の治療方法および/または予防方法

Country Status (9)

Country Link
US (1) US20230241064A1 (cg-RX-API-DMAC10.html)
EP (1) EP4087575A4 (cg-RX-API-DMAC10.html)
JP (1) JP7763761B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220124736A (cg-RX-API-DMAC10.html)
CN (1) CN115003306A (cg-RX-API-DMAC10.html)
CA (1) CA3164933A1 (cg-RX-API-DMAC10.html)
IL (1) IL294344B2 (cg-RX-API-DMAC10.html)
TW (1) TWI882058B (cg-RX-API-DMAC10.html)
WO (1) WO2021140418A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12551484B2 (en) 2019-11-05 2026-02-17 Resverlogix Corp. Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
AU2021368618B2 (en) 2020-10-30 2025-02-27 Resverlogix Corp. Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
KR20110135411A (ko) * 2009-03-27 2011-12-16 브리스톨-마이어스 스큅 컴퍼니 Dpp-iv 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법
US9034883B2 (en) * 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
BR112016003584A8 (pt) * 2013-08-21 2018-01-30 Resverlogix Corp composições farmaceuticas e uso das mesmas para regressão de placa acelerada
KR20160043118A (ko) * 2013-08-21 2016-04-20 리스버로직스 코퍼레이션 가속화된 경화반 퇴행을 위한 조성물 및 치료방법
JP2017528431A (ja) * 2014-07-17 2017-09-28 ジェローム シェンターク, 器官再生のための内因性回腸ブレーキホルモン経路の活性化、並びに関連する組成物、治療方法、診断、及び制御システム
US20190031774A1 (en) * 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
CN109824608B (zh) * 2019-03-15 2022-06-21 深圳晶泰科技有限公司 一种Apabetalone晶型及其制备方法

Similar Documents

Publication Publication Date Title
CN101374523B (zh) 用于治疗糖尿病的二肽基肽酶抑制剂
JP5780430B2 (ja) 勃起不全の処置用のPDE5阻害剤と組み合わせたsGC刺激剤またはsGC活性化剤
JP2006523216A5 (cg-RX-API-DMAC10.html)
JP2008515905A5 (cg-RX-API-DMAC10.html)
NZ593754A (en) Dpp-iv inhibitors for treatment of diabetes in paediatric patients
ES2532210T3 (es) Métodos para el tratamiento concomitante de teofilina y febuxostat
JP2023500685A5 (cg-RX-API-DMAC10.html)
WO2019046287A1 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEPATITIS B
JP2006518731A5 (cg-RX-API-DMAC10.html)
RU2005102110A (ru) Способ и лекарственное средство для лечения тяжелой сердечной недостаточности
EP4596044A2 (en) Combination therapy of gpr119 agonists and dpp-4 inhibitors
JP2022541503A (ja) Fxrアゴニストを使用した肝疾患の組み合わせ処置
JP2022552881A5 (cg-RX-API-DMAC10.html)
EP3820470B1 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators for use in treating portal hypertension
JP2018531273A5 (cg-RX-API-DMAC10.html)
FI4054584T3 (fi) Menetelmiä merkittävien sydän- ja verisuoniperäisten haittatapahtumien (mace) hoitamiseksi ja/tai ehkäisemiseksi bet-bromodomeenin estäjän ja natriumista riippuvaisen glukoosin kuljetusproteiinin 2:n estäjän yhdistelmällä
US10358447B2 (en) Substituted 2-N-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, and methods of making and using same
RU2334517C2 (ru) Средство, потенцирующее противоопухолевый эффект, и противоопухолевое средство
JP2023547475A5 (cg-RX-API-DMAC10.html)
JP7763761B2 (ja) Betブロモドメイン阻害剤およびジペプチジルペプチダーゼ4阻害剤の組合せによる主要有害心血管イベント(mace)の治療方法および/または予防方法
US12226411B2 (en) Soluble guanylate cyclase activators for treating portal hypertension
US20230019280A1 (en) Substituted isoindolonyl 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same
US20240366596A1 (en) Treatment of hfpef in post-menopausal women with an sgc stimulator
JP2009532494A5 (cg-RX-API-DMAC10.html)
WO2011002011A1 (ja) Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬